Just months after laying off a quarter of its workforce to fund a phase 2 study of its bloodstream infection preventive ...

Michael Yee, global head of biotech research at UBS, joins CNBC’s ‘Squawk on the Street’ to explain Moderna's narrower-than-expected loss, why healthcare is outperforming, and vaccine mandates and ...

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

Explore India's potential in bio-based chemicals and enzymes, highlighting industry leaders and challenges in sustainable ...

Capcom and biotech art group LOM BABY bring Resident Evil’s T-virus to Shibuya PARCO, explaining the exhibit, safety claims, and real biotech context ...

The Ethereum co-founder argues that prediction markets’ current focus on short-term crypto bets is putting them on a path to ...

Krystal Biotech received FDA RMAT designation for inhaled KB707 in advanced NSCLC, based on a 36% ORR in heavily pretreated ...

BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, ...

In an era of escalating biological threats, from weaponized pathogens to evolving viruses like Mpox, small U.S. biotechs are stepping up to bolster military readiness and national security.

Triphine Mukandanga, a potato farmer in Cyanika Sector, Burera District, describes the 2026 planting season as a difficult one that has left her questioning whether to continue with the crop after ...

Royalty Pharma delivered robust FY25 results, with double-digit growth in Royalty Receipts and Portfolio Receipts. Check out why RPRX stock is a buy.

If you’re an investor, it’s a good time to be long on longevity. The longevity economy is projected to be worth $27 trillion by 2030. Silicon Valley entrepreneurs are all in, investing in anti-aging ...